Barclays lowered the firm’s price target on Patterson-UTI (PTEN) to $7 from $8 and keeps an Overweight rating on the shares post the Q2 report. The company’s Q3 outlook reflects the softening activity and pricing environment in North America, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTEN:
- Patterson-UTI price target lowered to $10 from $12 at Stifel
- Patterson-UTI price target lowered to $8.50 from $9 at RBC Capital
- Patterson-UTI Energy Reports Q2 2025 Financial Results
- Patterson-UTI Energy Navigates Challenges with Optimism
- Patterson-UTI: Strong Financial Performance and Promising Outlook Support Buy Rating